Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/20/2019 05/21/2019 05/22/2019 05/23/2019 05/24/2019 Date
65.86(c) 66.52(c) 66.5(c) 67.17(c) 66.865 Last
4 508 787 5 118 549 5 764 757 6 707 321 1 999 094 Volume
-0.75% +1.00% -0.03% +1.01% -0.45% Change
More quotes
Financials (USD)
Sales 2019 22 035 M
EBIT 2019 11 437 M
Net income 2019 6 929 M
Debt 2019 5 969 M
Yield 2019 3,76%
Sales 2020 22 394 M
EBIT 2020 11 487 M
Net income 2020 7 007 M
Finance 2020 1 047 M
Yield 2020 4,06%
P/E ratio 2019 12,40
P/E ratio 2020 12,18
EV / Sales2019 4,15x
EV / Sales2020 3,77x
Capitalization 85 410 M
More Financials
Company
Gilead Sciences specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (98.5% of net sales) and other (1.5%; primarily... 
Sector
Biotechnology & Medical Research
Calendar
06/01 | 06:00pmPresentation
More about the company
Surperformance© ratings of Gilead Sciences
Trading Rating : Investor Rating :
More Ratings
Latest news on GILEAD SCIENCES
05/21GILEAD SCIENCES : to Present at the Jefferies 2019 Global Healthcare Conference ..
BU
05/15GILEAD SCIENCES : Kite to Present New Data From Leading Cell Therapy Portfolio a..
BU
05/15GILEAD SCIENCES : To Donate HIV Prevention Pill Truvada To 200,000 People
AQ
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
05/14GILEAD SCIENCES : Statement On Inaccurate Reporting On Truvada®
PU
05/11GILEAD SCIENCES : Goldfinch to team up against kidney disease
AQ
05/10GILEAD SCIENCES : HHS chief announce donation of HIV prevention drug Truvada
AQ
05/09GILEAD SCIENCES : Drugmaker will donate meds for US push to end HIV epidemic
AQ
05/09GILEAD SCIENCES : to Provide Free Truvada for PrEP® to Support U.S. Initiative t..
BU
05/09GILEAD SCIENCES INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal..
AQ
More news
Analyst Recommendations on GILEAD SCIENCES
More recommendations
Sector news : Bio Therapeutic Drugs
05/21Global chemical firms urged to source responsibly after lethal China blast - ..
RE
05/13REGENERON PHARMACEUTICALS : Says FDA Approves Eylea Injection for All Diabetic R..
DJ
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
05/09PATRICK THOMAS : Biotech Is Place to Be for Top Salaries
DJ
05/08GLOBAL MARKETS LIVE : Siemens, Airbus, Nestlé, Tesla…
More sector news : Bio Therapeutic Drugs
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 80,8 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES7.39%85 410
VERTEX PHARMACEUTICALS4.41%44 312
REGENERON PHARMACEUTICALS-14.30%33 962
GENMAB12.37%11 081
SAREPTA THERAPEUTICS INC8.36%8 769
BEIGENE LTD--.--%7 638